 Phio Pharmaceuticals Corp NASDAQ: PHIO stock falls despite the company announcing positive new in vivo data showing that PH-762 significantly enhanced the antitumor efficacy of HER2-targeted CAR-T cells HER2CART in solid tumors. Compared to untreated, HER2CART cells treated with PH-762 showed statistically significant and durable inhibition of tumor growth. 